CDHR5 and cancer: Additionally, present studies have suggested that CDHR5‐L was the major isoform regulating malignant behaviours of PDAC, while CDHR5‐M was dominantly expressed in other cancers, so specific sites of CDHR5‐L like the mucin domain would be designed as the therapeutic targets to prevent adverse effects on other organs and tissues.